Começar
ProfxCapital

SELLAS Announces Pricing of $15 Million Public Offering.

Viés de alta
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)  
ProfxCapital  
NASDAQ:SLS   SELLAS Life Sciences Group, Inc.
Beyond Technical Analysis stocksignals stockstrading stockstobuy stocksonthemove pennystocks pennybreakout publicoffering stockstowatch
3
0
beyondta stocksignals stockstrading stockstobuy stocksonthemove pennystocks pennybreakout publicoffering stockstowatch
SELLAS intends to use the net proceeds from the offering to commence a pivotal Phase 3 trial for its lead clinical candidate, galinpepimut-S (“GPS”), as a monotherapy in acute myeloid leukemia patients following second complete remission and to continue its Phase 1/2 basket type trial of GPS in combination with pembrolizumab, as well as for general corporate purposes and funding its working capital needs.
Aviso legal

As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.